The White House announced Friday that the TrumpRx prescription drug discount platform, launched in January 2026, would add three medications contributed by German pharmaceutical company Boehringer Ingelheim: Jentadueto and Jentadueto XR, both used to treat Type 2 diabetes, and Striverdi Respimat, a maintenance treatment for chronic obstructive pulmonary disease. The additions bring TrumpRx's total formulary to more than 30 drugs, all offered at steep discounts for uninsured patients paying out of pocket.
The price reductions are substantial on a per-unit basis. Jentadueto, typically listed at around $525, is offered on TrumpRx at approximately $55 — a reduction of nearly 90 percent. Striverdi Respimat, listed at around $276, is available for approximately $35. Ben Link, an analyst at the drug pricing firm 46brooklyn, told NBC News: "Those are pretty significant discounts." NBC News confirmed the additions and noted that TrumpRx functions as a self-pay portal connecting uninsured patients directly to manufacturer pricing, similar in structure to programs that pharmaceutical companies have historically offered on their own websites.
The platform's reach remains limited. A survey cited by NBC News found that about one-third of prescription drug users have heard of TrumpRx, but only 7 percent have visited the site to compare prices. Among users of GLP-1 medications — among the most expensive and widely discussed drug categories — 16 percent had visited. HHS officials acknowledged in background briefings that TrumpRx "was never meant to be used by people with health insurance," who represent the majority of prescription users. The White House has not disclosed actual transaction volumes or the number of patients served.
Fox Business and the Daily Wire framed TrumpRx as a meaningful fulfillment of Trump's State of the Union pledge to lower prescription drug costs, noting that the platform has grown from a handful of manufacturers to include drugs from multiple large pharmaceutical companies since January. Health economists cited by NPR cautioned that TrumpRx addresses a real but narrow need — providing relief to the roughly 25 million Americans with no prescription coverage — while leaving untouched the broader insured-patient cost structure that accounts for the vast majority of U.S. prescription spending. Democrats have called for Medicare drug price negotiation authority as a more comprehensive approach.
Left-Leaning Emphasis
- NPR and health economists argue that TrumpRx, while providing real relief for a narrow population of uninsured cash-payers, fails to address the systemic cost structures that affect the vast majority of the 300 million Americans with insurance — and that Democrats' Medicare negotiation authority proposal would deliver far broader savings.
- Left-leaning health coverage notes that TrumpRx essentially replicates manufacturer patient-assistance programs that already existed, raising questions about whether the platform represents genuine policy innovation or political branding of existing industry discounts.
Right-Leaning Emphasis
- Fox Business and the Daily Wire celebrate TrumpRx as a direct delivery on Trump's drug pricing promise, emphasizing the near-90-percent per-unit reductions and the growing formulary as evidence of pharmaceutical industry cooperation with administration pricing goals.
- Conservative outlets argue that a voluntary market-based approach — incentivizing manufacturers to participate rather than mandating price controls — is more sustainable and less likely to reduce investment in new drug development than Democratic alternatives.
Sources
- NBC News Mar 21
- Fox Business Mar 21
- NPR Mar 21
- Daily Wire Mar 21